{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T19:21:44Z","timestamp":1790623304202,"version":"4.1.0"},"reference-count":283,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,10,7]],"date-time":"2020-10-07T00:00:00Z","timestamp":1602028800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010771","name":"Loo och Hans Ostermans Stiftelse f\u00f6r Medicinsk Forskning","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010771","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009673","name":"Gun och Bertil Stohnes Stiftelse","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009673","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018163","name":"Margareta af Ugglas Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018163","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004359","name":"Vetenskapsr\u00e5det","doi-asserted-by":"publisher","award":["2015\\u201302774"],"award-info":[{"award-number":["2015\\u201302774"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004359","name":"Vetenskapsr\u00e5det","doi-asserted-by":"publisher","award":["2018\\u201302843"],"award-info":[{"award-number":["2018\\u201302843"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002742","name":"Banaras Hindu University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002742","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004047","name":"Karolinska Institutet","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004047","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003792","name":"Hj\u00e4rnfonden","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003792","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006285","name":"Magnus Bergvalls Stiftelse","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006285","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018850","name":"Gunvor och Josef An\u00e9rs Siftelse","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018850","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010815","name":"Stiftelsen f\u00f6r Gamla Tj\u00e4narinnor","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010815","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1016\/j.ejmech.2020.112915","type":"journal-article","created":{"date-parts":[[2020,10,15]],"date-time":"2020-10-15T12:05:12Z","timestamp":1602763512000},"page":"112915","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":86,"special_numbering":"C","title":["Small molecule therapeutics for tauopathy in Alzheimer\u2019s disease: Walking on the path of most resistance"],"prefix":"10.1016","volume":"209","author":[{"given":"Lisha","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Bharti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7021-6996","authenticated-orcid":false,"given":"Rajnish","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pavel F.","family":"Pavlov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bengt","family":"Winblad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2020.112915_bib1","article-title":"Can inflammation be resolved in Alzheimer\u2019s disease?","volume":"11","author":"Zhu","year":"2018","journal-title":"Ther. Adv. Neurol. Diso."},{"key":"10.1016\/j.ejmech.2020.112915_bib2","first-page":"19","article-title":"Are NSAIDs useful to treat Alzheimer\u2019s disease or mild cognitive impairment?","volume":"2","author":"Imbimbo","year":"2010","journal-title":"Front. Aging Neurosci."},{"key":"10.1016\/j.ejmech.2020.112915_bib3","first-page":"271","article-title":"Identification of cDNA clones for the human microtubule-associated protein tau and chromosomal localization of the genes for tau and microtubule-associated protein 2","volume":"387","author":"Neve","year":"1986","journal-title":"Brain Res."},{"key":"10.1016\/j.ejmech.2020.112915_bib4","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/0896-6273(89)90210-9","article-title":"Multiple isoforms of human microtubule-associated protein tau: sequences and localization in neurofibrillary tangles of Alzheimer\u2019s disease","volume":"3","author":"Goedert","year":"1989","journal-title":"Neuron"},{"key":"10.1016\/j.ejmech.2020.112915_bib5","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1002\/j.1460-2075.1989.tb03390.x","article-title":"Cloning and sequencing of the cDNA encoding an isoform of microtubule-associated protein tau containing four tandem repeats: differential expression of tau protein mRNAs in human brain","volume":"8","author":"Goedert","year":"1989","journal-title":"EMBO J."},{"key":"10.1016\/j.ejmech.2020.112915_bib6","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.pneurobio.2018.12.005","article-title":"It\u2019s all about tau","volume":"175","author":"Tapia-Rojas","year":"2019","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.ejmech.2020.112915_bib7","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/0306-4522(87)90276-4","article-title":"The expression and distribution of the microtubule-associated proteins tau and microtubule-associated protein 2 in hippocampal neurons in the rat in situ and in cell culture","volume":"23","author":"Dotti","year":"1987","journal-title":"Neuroscience"},{"key":"10.1016\/j.ejmech.2020.112915_bib8","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.cell.2010.06.036","article-title":"Dendritic function of tau mediates amyloid-beta toxicity in Alzheimer\u2019s disease mouse models","volume":"142","author":"Ittner","year":"2010","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2020.112915_bib9","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1073\/pnas.0607919104","article-title":"Multiple-motor based transport and its regulation by Tau","volume":"104","author":"Vershinin","year":"2007","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ejmech.2020.112915_bib10","doi-asserted-by":"crossref","first-page":"4913","DOI":"10.1073\/pnas.83.13.4913","article-title":"Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology","volume":"83","author":"Grundke-Iqbal","year":"1986","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ejmech.2020.112915_bib11","doi-asserted-by":"crossref","first-page":"4044","DOI":"10.1073\/pnas.83.11.4044","article-title":"Microtubule-associated protein tau (tau) is a major antigenic component of paired helical filaments in Alzheimer disease","volume":"83","author":"Kosik","year":"1986","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ejmech.2020.112915_bib12","doi-asserted-by":"crossref","first-page":"24374","DOI":"10.1016\/S0021-9258(20)80536-5","article-title":"Microtubule-associated protein tau. Abnormal phosphorylation of a non-paired helical filament pool in Alzheimer disease","volume":"268","author":"Kopke","year":"1993","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ejmech.2020.112915_bib13","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/0896-6273(93)90279-Z","article-title":"Phosphorylation of Ser262 strongly reduces binding of tau to microtubules: distinction between PHF-like immunoreactivity and microtubule binding","volume":"11","author":"Biernat","year":"1993","journal-title":"Neuron"},{"key":"10.1016\/j.ejmech.2020.112915_bib14","doi-asserted-by":"crossref","first-page":"5301","DOI":"10.1016\/S0021-9258(17)42989-9","article-title":"Phosphorylation affects the ability of tau protein to promote microtubule assembly","volume":"259","author":"Lindwall","year":"1984","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ejmech.2020.112915_bib15","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1016\/j.neuron.2010.11.030","article-title":"Tau mislocalization to dendritic spines mediates synaptic dysfunction independently of neurodegeneration","volume":"68","author":"Hoover","year":"2010","journal-title":"Neuron"},{"key":"10.1016\/j.ejmech.2020.112915_bib16","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/j.neuron.2010.08.044","article-title":"Acetylation of tau inhibits its degradation and contributes to tauopathy","volume":"67","author":"Min","year":"2010","journal-title":"Neuron"},{"key":"10.1016\/j.ejmech.2020.112915_bib17","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/ncomms1255","article-title":"The acetylation of tau inhibits its function and promotes pathological tau aggregation","volume":"2","author":"Cohen","year":"2011","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2020.112915_bib18","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1007\/s004010050477","article-title":"Staging the pathological assembly of truncated tau protein into paired helical filaments in Alzheimer\u2019s disease","volume":"91","author":"Mena","year":"1996","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.ejmech.2020.112915_bib19","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S0891-0618(01)00096-5","article-title":"Accumulation of C-terminally truncated tau protein associated with vulnerability of the perforant pathway in early stages of neurofibrillary pathology in Alzheimer\u2019s disease","volume":"22","author":"Garcia-Sierra","year":"2001","journal-title":"J.\u00a0Chem. Neuroanat."},{"key":"10.1016\/j.ejmech.2020.112915_bib20","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1006\/nbdi.2000.0335","article-title":"Proapoptotic effects of tau cleavage product generated by caspase-3","volume":"8","author":"Chung","year":"2001","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.ejmech.2020.112915_bib21","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1172\/JCI200420640","article-title":"Caspase-cleavage of tau is an early event in Alzheimer disease tangle pathology","volume":"114","author":"Rissman","year":"2004","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.ejmech.2020.112915_bib22","doi-asserted-by":"crossref","first-page":"10032","DOI":"10.1073\/pnas.1630428100","article-title":"Caspase cleavage of tau: linking amyloid and neurofibrillary tangles in Alzheimer\u2019s disease","volume":"100","author":"Gamblin","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ejmech.2020.112915_bib23","doi-asserted-by":"crossref","first-page":"24","DOI":"10.3389\/fncel.2015.00024","article-title":"Truncated tau deregulates synaptic markers in rat model for human tauopathy","volume":"9","author":"Jadhav","year":"2015","journal-title":"Front. Cell. Neurosci."},{"key":"10.1016\/j.ejmech.2020.112915_bib24","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1038\/nm0896-871","article-title":"Glycosylation of microtubule-associated protein tau: an abnormal posttranslational modification in Alzheimer\u2019s disease","volume":"2","author":"Wang","year":"1996","journal-title":"Nat. Med."},{"key":"10.1016\/j.ejmech.2020.112915_bib25","doi-asserted-by":"crossref","first-page":"15120","DOI":"10.1073\/pnas.1606899113","article-title":"Loss of O-GlcNAc glycosylation in forebrain excitatory neurons induces neurodegeneration","volume":"113","author":"Wang","year":"2016","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ejmech.2020.112915_bib26","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1093\/brain\/awp099","article-title":"Reduced O-GlcNAcylation links lower brain glucose metabolism and tau pathology in Alzheimer\u2019s disease","volume":"132","author":"Liu","year":"2009","journal-title":"Brain"},{"key":"10.1016\/j.ejmech.2020.112915_bib27","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1021\/acschemneuro.9b00143","article-title":"O-GlcNAc modification protects against protein misfolding and aggregation in neurodegenerative disease","volume":"10","author":"Ryan","year":"2019","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.ejmech.2020.112915_bib28","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1126\/science.3029875","article-title":"Ubiquitin is a component of paired helical filaments in Alzheimer\u2019s disease","volume":"235","author":"Mori","year":"1987","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2020.112915_bib29","doi-asserted-by":"crossref","first-page":"10825","DOI":"10.1074\/jbc.M512786200","article-title":"Alzheimer disease-specific conformation of hyperphosphorylated paired helical filament-Tau is polyubiquitinated through Lys-48, Lys-11, and Lys-6 ubiquitin conjugation","volume":"281","author":"Cripps","year":"2006","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ejmech.2020.112915_bib30","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s00401-011-0893-0","article-title":"Dual modification of Alzheimer\u2019s disease PHF-tau protein by lysine methylation and ubiquitylation: a mass spectrometry approach","volume":"123","author":"Thomas","year":"2012","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.ejmech.2020.112915_bib31","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1007\/s12017-013-8257-7","article-title":"SUMO and Alzheimer\u2019s disease","volume":"15","author":"Lee","year":"2013","journal-title":"NeuroMolecular Med."},{"key":"10.1016\/j.ejmech.2020.112915_bib32","doi-asserted-by":"crossref","first-page":"16586","DOI":"10.1073\/pnas.1417548111","article-title":"SUMOylation at K340 inhibits tau degradation through deregulating its phosphorylation and ubiquitination","volume":"111","author":"Luo","year":"2014","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ejmech.2020.112915_bib33","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1016\/j.ajpath.2011.01.030","article-title":"Tyrosine nitration within the proline-rich region of Tau in Alzheimer\u2019s disease","volume":"178","author":"Reyes","year":"2011","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.ejmech.2020.112915_bib34","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/S0002-9440(10)65659-3","article-title":"Advanced glycation end products in Alzheimer\u2019s disease and other neurodegenerative diseases","volume":"153","author":"Sasaki","year":"1998","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.ejmech.2020.112915_bib35","doi-asserted-by":"crossref","first-page":"979","DOI":"10.3233\/JAD-190604","article-title":"Quantification of tau protein lysine methylation in aging and Alzheimer\u2019s disease","volume":"71","author":"Huseby","year":"2019","journal-title":"J.\u00a0Alzheimers Dis."},{"key":"10.1016\/j.ejmech.2020.112915_bib36","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1038\/21650","article-title":"The prolyl isomerase Pin1 restores the function of Alzheimer-associated phosphorylated tau protein","volume":"399","author":"Lu","year":"1999","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2020.112915_bib37","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.cell.2012.02.016","article-title":"Proline isomer-specific antibodies reveal the early pathogenic tau conformation in Alzheimer\u2019s disease","volume":"149","author":"Nakamura","year":"2012","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2020.112915_bib38","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.brainresbull.2016.08.018","article-title":"Tau and tauopathies","volume":"126","author":"Arendt","year":"2016","journal-title":"Brain Res. Bull."},{"key":"10.1016\/j.ejmech.2020.112915_bib39","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1038\/197192b0","article-title":"Paired helical filaments in electron microscopy of Alzheimer\u2019s disease","volume":"197","author":"Kidd","year":"1963","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2020.112915_bib40","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1073\/pnas.88.6.2288","article-title":"Straight and paired helical filaments in Alzheimer disease have a common structural unit","volume":"88","author":"Crowther","year":"1991","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ejmech.2020.112915_bib41","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1159\/000353687","article-title":"Prefibrillar tau oligomers in mild cognitive impairment and Alzheimer\u2019s disease","volume":"13","author":"Mufson","year":"2014","journal-title":"Neurodegener. Dis."},{"key":"10.1016\/j.ejmech.2020.112915_bib42","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.bbadis.2004.09.010","article-title":"Tau aggregation is driven by a transition from random coil to beta sheet structure","volume":"1739","author":"von Bergen","year":"2005","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.ejmech.2020.112915_bib43","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/BF00308809","article-title":"Neuropathological stageing of Alzheimer-related changes","volume":"82","author":"Braak","year":"1991","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.ejmech.2020.112915_bib44","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/S0197-4580(97)00056-0","article-title":"Frequency of stages of Alzheimer-related lesions in different age categories","volume":"18","author":"Braak","year":"1997","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.ejmech.2020.112915_bib45","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1212\/WNL.42.3.631","article-title":"Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer\u2019s disease","volume":"42","author":"Arriagada","year":"1992","journal-title":"Neurology"},{"key":"10.1016\/j.ejmech.2020.112915_bib46","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1001\/archneur.1995.00540250089017","article-title":"Neocortical neurofibrillary tangles correlate with dementia severity in Alzheimer\u2019s disease","volume":"52","author":"Bierer","year":"1995","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.ejmech.2020.112915_bib47","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1212\/01.WNL.0000063311.58879.01","article-title":"Tangle and neuron numbers, but not amyloid load, predict cognitive status in Alzheimer\u2019s disease","volume":"60","author":"Giannakopoulos","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.ejmech.2020.112915_bib48","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1097\/00005072-199903000-00007","article-title":"Quantitative decrease in synaptophysin message expression and increase in cathepsin D message expression in Alzheimer disease neurons containing neurofibrillary tangles","volume":"58","author":"Callahan","year":"1999","journal-title":"J.\u00a0Neuropathol. Exp. Neurol."},{"key":"10.1016\/j.ejmech.2020.112915_bib49","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1046\/j.1471-4159.2003.01642.x","article-title":"Proteasome inhibition by paired helical filament-tau in brains of patients with Alzheimer\u2019s disease","volume":"85","author":"Keck","year":"2003","journal-title":"J.\u00a0Neurochem."},{"key":"10.1016\/j.ejmech.2020.112915_bib50","doi-asserted-by":"crossref","first-page":"83","DOI":"10.3389\/fnagi.2017.00083","article-title":"Tau oligomers: cytotoxicity, propagation, and mitochondrial damage","volume":"9","author":"Shafiei","year":"2017","journal-title":"Front. Aging Neurosci."},{"key":"10.1016\/j.ejmech.2020.112915_bib51","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.neures.2005.11.009","article-title":"Increased levels of granular tau oligomers: an early sign of brain aging and Alzheimer\u2019s disease","volume":"54","author":"Maeda","year":"2006","journal-title":"Neurosci. Res."},{"key":"10.1016\/j.ejmech.2020.112915_bib52","doi-asserted-by":"crossref","first-page":"14234","DOI":"10.1523\/JNEUROSCI.1523-15.2015","article-title":"Internalized tau oligomers cause neurodegeneration by inducing accumulation of pathogenic tau in human neurons derived from induced pluripotent stem cells","volume":"35","author":"Usenovic","year":"2015","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.ejmech.2020.112915_bib53","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/1750-1326-6-39","article-title":"Tau oligomers impair memory and induce synaptic and mitochondrial dysfunction in wild-type mice","volume":"6","author":"Lasagna-Reeves","year":"2011","journal-title":"Mol. Neurodegener."},{"issue":"1","key":"10.1016\/j.ejmech.2020.112915_bib54","doi-asserted-by":"crossref","first-page":"S97","DOI":"10.3233\/JAD-132477","article-title":"Specific targeting of tau oligomers in Htau mice prevents cognitive impairment and tau toxicity following injection with brain-derived tau oligomeric seeds","volume":"40","author":"Castillo-Carranza","year":"2014","journal-title":"J.\u00a0Alzheimers Dis."},{"key":"10.1016\/j.ejmech.2020.112915_bib55","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.bj.2018.01.003","article-title":"Tau and neuroinflammation: what impact for Alzheimer\u2019s disease and tauopathies?","volume":"41","author":"Laurent","year":"2018","journal-title":"Biomed. J."},{"key":"10.1016\/j.ejmech.2020.112915_bib56","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/s41582-018-0013-z","article-title":"Tau-targeting therapies for Alzheimer disease","volume":"14","author":"Congdon","year":"2018","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.ejmech.2020.112915_bib57","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/j.jalz.2016.06.006","article-title":"Therapeutic strategies for the treatment of tauopathies: hopes and challenges","volume":"12","author":"Khanna","year":"2016","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.ejmech.2020.112915_bib58","doi-asserted-by":"crossref","first-page":"3","DOI":"10.2174\/1567205052772713","article-title":"Current advances on different kinases involved in tau phosphorylation, and implications in Alzheimer\u2019s disease and tauopathies","volume":"2","author":"Ferrer","year":"2005","journal-title":"Curr. Alzheimer Res."},{"key":"10.1016\/j.ejmech.2020.112915_bib59","doi-asserted-by":"crossref","first-page":"1942","DOI":"10.1111\/j.1460-9568.2005.04391.x","article-title":"Contributions of protein phosphatases PP1, PP2A, PP2B and PP5 to the regulation of tau phosphorylation","volume":"22","author":"Liu","year":"2005","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.ejmech.2020.112915_bib60","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.tibs.2007.12.004","article-title":"PP2A holoenzyme assembly: in cauda venenum (the sting is in the tail)","volume":"33","author":"Janssens","year":"2008","journal-title":"Trends Biochem. Sci."},{"key":"10.1016\/j.ejmech.2020.112915_bib61","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.molcel.2009.02.015","article-title":"From promiscuity to precision: protein phosphatases get a makeover","volume":"33","author":"Virshup","year":"2009","journal-title":"Mol. Cell."},{"key":"10.1016\/j.ejmech.2020.112915_bib62","doi-asserted-by":"crossref","first-page":"13888","DOI":"10.1073\/pnas.1009038107","article-title":"Sodium selenate mitigates tau pathology, neurodegeneration, and functional deficits in Alzheimer\u2019s disease models","volume":"107","author":"van Eersel","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ejmech.2020.112915_bib63","doi-asserted-by":"crossref","first-page":"223","DOI":"10.3233\/JAD-160544","article-title":"A\u00a0phase IIa randomized control trial of VEL015 (sodium selenate) in mild-moderate Alzheimer\u2019s disease","volume":"54","author":"Malpas","year":"2016","journal-title":"J.\u00a0Alzheimers Dis."},{"key":"10.1016\/j.ejmech.2020.112915_bib64","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1007\/s13311-018-0662-z","article-title":"Supranutritional sodium selenate supplementation delivers selenium to the central nervous system: results from a randomized controlled pilot trial in Alzheimer\u2019s disease","volume":"16","author":"Cardoso","year":"2019","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.ejmech.2020.112915_bib65","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1056\/NEJMoa013128","article-title":"Memantine in moderate-to-severe Alzheimer\u2019s disease","volume":"348","author":"Reisberg","year":"2003","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ejmech.2020.112915_bib66","doi-asserted-by":"crossref","first-page":"3973","DOI":"10.1016\/j.febslet.2006.06.021","article-title":"Involvement of I2PP2A in the abnormal hyperphosphorylation of tau and its reversal by Memantine","volume":"580","author":"Chohan","year":"2006","journal-title":"FEBS Lett."},{"key":"10.1016\/j.ejmech.2020.112915_bib67","doi-asserted-by":"crossref","first-page":"2535","DOI":"10.4049\/jimmunol.1002847","article-title":"Apolipoprotein E and peptide mimetics modulate inflammation by binding the SET protein and activating protein phosphatase 2A","volume":"186","author":"Christensen","year":"2011","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.ejmech.2020.112915_bib68","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1159\/000334914","article-title":"APOE-mimetic peptides reduce behavioral deficits, plaques and tangles in Alzheimer\u2019s disease transgenics","volume":"10","author":"Vitek","year":"2012","journal-title":"Neurodegener. Dis."},{"key":"10.1016\/j.ejmech.2020.112915_bib69","doi-asserted-by":"crossref","first-page":"e229","DOI":"10.1016\/S1470-2045(12)70558-2","article-title":"Protein phosphatase 2A: a target for anticancer therapy","volume":"14","author":"Perrotti","year":"2013","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ejmech.2020.112915_bib70","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/s12017-019-08558-2","article-title":"Beneficial effects of Fingolimod in Alzheimer\u2019s disease: molecular mechanisms and therapeutic potential","volume":"21","author":"Angelopoulou","year":"2019","journal-title":"NeuroMolecular Med."},{"key":"10.1016\/j.ejmech.2020.112915_bib71","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.brainres.2017.01.014","article-title":"The sphingosine-1-phosphate receptor 1 agonist SEW2871 reduces Tau-Ser262 phosphorylation in rat hippocampal slices","volume":"1658","author":"St-Cyr Gigu\u00e8re","year":"2017","journal-title":"Brain Res."},{"key":"10.1016\/j.ejmech.2020.112915_bib72","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.celrep.2018.06.009","article-title":"CIP2A causes tau\/APP phosphorylation, synaptopathy, and memory deficits in Alzheimer\u2019s disease","volume":"24","author":"Shentu","year":"2018","journal-title":"Cell Rep."},{"key":"10.1016\/j.ejmech.2020.112915_bib73","doi-asserted-by":"crossref","first-page":"732","DOI":"10.2174\/1567205016666190830113420","article-title":"Genistein decreases APP\/tau phosphorylation and ameliorates A\u03b2 overproduction through inhibiting CIP2A","volume":"16","author":"Shentu","year":"2019","journal-title":"Curr. Alzheimer Res."},{"key":"10.1016\/j.ejmech.2020.112915_bib74","doi-asserted-by":"crossref","first-page":"21830","DOI":"10.1073\/pnas.0912793107","article-title":"Biguanide metformin acts on tau phosphorylation via mTOR\/protein phosphatase 2A (PP2A) signaling","volume":"107","author":"Kickstein","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ejmech.2020.112915_bib75","doi-asserted-by":"crossref","first-page":"13753","DOI":"10.1038\/s41598-017-12974-4","article-title":"Resveratrol induces dephosphorylation of Tau by interfering with the MID1-PP2A complex","volume":"7","author":"Schweiger","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejmech.2020.112915_bib76","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1093\/jnen\/63.10.1080","article-title":"Downregulation of protein phosphatase 2A carboxyl methylation and methyltransferase may contribute to Alzheimer disease pathogenesis","volume":"63","author":"Sontag","year":"2004","journal-title":"J.\u00a0Neuropathol. Exp. Neurol."},{"key":"10.1016\/j.ejmech.2020.112915_bib77","doi-asserted-by":"crossref","first-page":"682","DOI":"10.3389\/fphar.2018.00682","article-title":"Cornel iridoid glycoside inhibits tau hyperphosphorylation via regulating cross-talk between GSK-3\u03b2 and PP2A signaling","volume":"9","author":"Yang","year":"2018","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejmech.2020.112915_bib78","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1194\/jlr.M300347-JLR200","article-title":"The structural requirements for ceramide activation of serine-threonine protein phosphatases","volume":"45","author":"Chalfant","year":"2004","journal-title":"J.\u00a0Lipid Res."},{"key":"10.1016\/j.ejmech.2020.112915_bib79","doi-asserted-by":"crossref","first-page":"3837","DOI":"10.1038\/onc.2009.244","article-title":"Dithiolethione compounds inhibit Akt signaling in human breast and lung cancer cells by increasing PP2A activity","volume":"28","author":"Switzer","year":"2009","journal-title":"Oncogene"},{"key":"10.1016\/j.ejmech.2020.112915_bib80","doi-asserted-by":"crossref","first-page":"5107","DOI":"10.1073\/pnas.0730817100","article-title":"Xylulose 5-phosphate mediates glucose-induced lipogenesis by xylulose 5-phosphate-activated protein phosphatase in rat liver","volume":"100","author":"Kabashima","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ejmech.2020.112915_bib81","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1007\/s10495-012-0715-4","article-title":"Carnosic acid modulates Akt\/IKK\/NF-\u03baB signaling by PP2A and induces intrinsic and extrinsic pathway mediated apoptosis in human prostate carcinoma PC-3 cells","volume":"17","author":"Kar","year":"2012","journal-title":"Apoptosis"},{"key":"10.1016\/j.ejmech.2020.112915_bib82","doi-asserted-by":"crossref","first-page":"5129","DOI":"10.1021\/jm901902w","article-title":"Synthesis, inhibitory activity of cholinesterases, and neuroprotective profile of novel 1,8-naphthyridine derivatives","volume":"53","author":"de Los R\u00edos","year":"2010","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2020.112915_bib83","doi-asserted-by":"crossref","first-page":"6963","DOI":"10.1523\/JNEUROSCI.6513-10.2011","article-title":"Enhanced phosphatase activity attenuates \u03b1-synucleinopathy in a mouse model","volume":"31","author":"Lee","year":"2011","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.ejmech.2020.112915_bib84","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/S0022-2836(02)00538-7","article-title":"Sequence and structure classification of kinases","volume":"320","author":"Cheek","year":"2002","journal-title":"J.\u00a0Mol. Biol."},{"key":"10.1016\/j.ejmech.2020.112915_bib85","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.ejmech.2016.02.018","article-title":"Design strategies, structure activity relationship and mechanistic insights for purines as kinase inhibitors","volume":"112","author":"Sharma","year":"2016","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2020.112915_bib86","doi-asserted-by":"crossref","first-page":"66","DOI":"10.4103\/2542-3975.216580","article-title":"An update on clinical trials targeting human tauopathies","volume":"2","author":"Javidnia","year":"2017","journal-title":"Clin. Trials Degener. Dis."},{"key":"10.1016\/j.ejmech.2020.112915_bib87","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.arr.2012.06.003","article-title":"Tau protein kinases: involvement in Alzheimer\u2019s disease","volume":"12","author":"Martin","year":"2013","journal-title":"Ageing Res. Rev."},{"key":"10.1016\/j.ejmech.2020.112915_bib88","doi-asserted-by":"crossref","first-page":"189","DOI":"10.3389\/fncel.2013.00189","article-title":"Recent developments of protein kinase inhibitors as potential AD therapeutics","volume":"7","author":"Tell","year":"2013","journal-title":"Front. Cell. Neurosci."},{"key":"10.1016\/j.ejmech.2020.112915_bib89","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.ejmech.2015.10.018","article-title":"Pivotal role of glycogen synthase kinase-3: a therapeutic target for Alzheimer\u2019s disease","volume":"107","author":"Maqbool","year":"2016","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2020.112915_bib90","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.brainresbull.2017.05.006","article-title":"Cyclin dependent kinase 5: a novel avenue for Alzheimer\u2019s disease","volume":"132","author":"Bhounsule","year":"2017","journal-title":"Brain Res. Bull."},{"key":"10.1016\/j.ejmech.2020.112915_bib91","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.biopsych.2017.06.004","article-title":"Targeting Fyn kinase in Alzheimer\u2019s disease","volume":"83","author":"Nygaard","year":"2018","journal-title":"Biol. Psychiatr."},{"key":"10.1016\/j.ejmech.2020.112915_bib92","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.ejmech.2018.08.093","article-title":"DYRK1A kinase inhibition with emphasis on neurodegeneration: a comprehensive evolution story-cum-perspective","volume":"158","author":"Pathak","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2020.112915_bib93","doi-asserted-by":"crossref","first-page":"205","DOI":"10.3233\/JAD-2012-120805","article-title":"Treatment of Alzheimer\u2019s disease with the GSK-3 inhibitor tideglusib: a pilot study","volume":"33","author":"del Ser","year":"2013","journal-title":"J.\u00a0Alzheimers Dis."},{"key":"10.1016\/j.ejmech.2020.112915_bib94","doi-asserted-by":"crossref","first-page":"75","DOI":"10.3233\/JAD-141959","article-title":"A\u00a0phase II trial of tideglusib in Alzheimer\u2019s disease","volume":"45","author":"Lovestone","year":"2015","journal-title":"J.\u00a0Alzheimers Dis."},{"key":"10.1016\/j.ejmech.2020.112915_bib95","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1001\/jamapsychiatry.2017.2362","article-title":"Association of lithium in drinking water with the incidence of dementia","volume":"74","author":"Kessing","year":"2017","journal-title":"JAMA Psychiatr."},{"key":"10.1016\/j.ejmech.2020.112915_bib96","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1111\/j.1399-5618.2009.00788.x","article-title":"Does lithium protect against dementia?","volume":"12","author":"Kessing","year":"2010","journal-title":"Bipolar Disord."},{"key":"10.1016\/j.ejmech.2020.112915_bib97","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1097\/01.wad.0000155068.23937.9b","article-title":"Does lithium therapy protect against the onset of dementia?","volume":"19","author":"Dunn","year":"2005","journal-title":"Alzheimer Dis. Assoc. Disord."},{"key":"10.1016\/j.ejmech.2020.112915_bib98","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1080\/13651500600810133","article-title":"Does long-term medication with lithium, clozapine or antidepressants prevent or attenuate dementia in bipolar and depressed patients?","volume":"11","author":"Angst","year":"2007","journal-title":"Int. J. Psychiat. Clin."},{"key":"10.1016\/j.ejmech.2020.112915_bib99","doi-asserted-by":"crossref","first-page":"425","DOI":"10.3233\/JAD-170744","article-title":"Examining the relationship between trace lithium in drinking water and the rising rates of age-Adjusted Alzheimer\u2019s disease mortality in Texas","volume":"61","author":"Fajardo","year":"2018","journal-title":"J.\u00a0Alzheimers Dis."},{"key":"10.1016\/j.ejmech.2020.112915_bib100","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1016\/j.pnpbp.2006.04.020","article-title":"Lithium and dementia: a preliminary study","volume":"30","author":"Terao","year":"2006","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.ejmech.2020.112915_bib101","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1192\/bjp.bp.106.029868","article-title":"Lithium and risk for Alzheimer\u2019s disease in elderly patients with bipolar disorder","volume":"190","author":"Nunes","year":"2007","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.ejmech.2020.112915_bib102","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1192\/bjp.bp.114.154047","article-title":"Lithium treatment and risk for dementia in adults with bipolar disorder: population-based cohort study","volume":"207","author":"Gerhard","year":"2015","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.ejmech.2020.112915_bib103","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1001\/archpsyc.65.11.1331","article-title":"Lithium treatment and risk of dementia","volume":"65","author":"Kessing","year":"2008","journal-title":"Arch. Gen. Psychiatr."},{"key":"10.1016\/j.ejmech.2020.112915_bib104","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1192\/bjp.bp.110.080044","article-title":"Disease-modifying properties of long-term lithium treatment for amnestic mild cognitive impairment: randomised controlled trial","volume":"198","author":"Forlenza","year":"2011","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.ejmech.2020.112915_bib105","doi-asserted-by":"crossref","first-page":"403","DOI":"10.3233\/JAD-150437","article-title":"Lithium as a treatment for Alzheimer\u2019s disease: a systematic review and meta-analysis","volume":"48","author":"Matsunaga","year":"2015","journal-title":"J.\u00a0Alzheimers Dis."},{"key":"10.1016\/j.ejmech.2020.112915_bib106","doi-asserted-by":"crossref","first-page":"922","DOI":"10.4088\/JCP.08m04606","article-title":"Lithium trial in Alzheimer\u2019s disease: a randomized, single-blind, placebo-controlled, multicenter 10-week study","volume":"70","author":"Hampel","year":"2009","journal-title":"J.\u00a0Clin. Psychiatr."},{"key":"10.1016\/j.ejmech.2020.112915_bib107","first-page":"104","article-title":"Microdose lithium treatment stabilized cognitive impairment in patients with Alzheimer\u2019s disease","volume":"10","author":"Nunes","year":"2013","journal-title":"Curr. Alzheimer Res."},{"key":"10.1016\/j.ejmech.2020.112915_bib108","first-page":"1","article-title":"Clinical and biological effects of long-term lithium treatment in older adults with amnestic mild cognitive impairment: randomised clinical trial","author":"Forlenza","year":"2019","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.ejmech.2020.112915_bib109","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.cct.2018.05.019","article-title":"Lithium treatment for agitation in Alzheimer\u2019s disease (Lit-AD): clinical rationale and study design","volume":"71","author":"Devanand","year":"2018","journal-title":"Contemp. Clin. Trials"},{"key":"10.1016\/j.ejmech.2020.112915_bib110","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s13195-015-0119-0","article-title":"A\u00a0phase Ib multiple ascending dose study of the safety, tolerability, and central nervous system availability of AZD0530 (saracatinib) in Alzheimer\u2019s disease","volume":"7","author":"Nygaard","year":"2015","journal-title":"Alzheimer\u2019s Res. Ther."},{"key":"10.1016\/j.ejmech.2020.112915_bib111","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1001\/jamaneurol.2019.2050","article-title":"Effect of AZD0530 on cerebral metabolic decline in Alzheimer disease: a randomized clinical trial","volume":"76","author":"van Dyck","year":"2019","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.ejmech.2020.112915_bib112","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1038\/nm.3951","article-title":"Critical role of acetylation in tau-mediated neurodegeneration and cognitive deficits","volume":"21","author":"Min","year":"2015","journal-title":"Nat. Med."},{"key":"10.1016\/j.ejmech.2020.112915_bib113","author":"US National Library of Medicine"},{"key":"10.1016\/j.ejmech.2020.112915_bib114","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.chembiol.2010.03.006","article-title":"Virtual ligand screening of the p300\/CBP histone acetyltransferase: identification of a selective small molecule inhibitor","volume":"17","author":"Bowers","year":"2010","journal-title":"Chem. Biol."},{"key":"10.1016\/j.ejmech.2020.112915_bib115","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.aao6765","article-title":"Nitrosylation of GAPDH augments pathological tau acetylation upon exposure to amyloid-beta","volume":"11","author":"Sen","year":"2018","journal-title":"Sci. Signal."},{"key":"10.1016\/j.ejmech.2020.112915_bib117","doi-asserted-by":"crossref","first-page":"3680","DOI":"10.1523\/JNEUROSCI.2369-17.2018","article-title":"SIRT1 deacetylates tau and reduces pathogenic tau spread in a mouse model of tauopathy","volume":"38","author":"Min","year":"2018","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.ejmech.2020.112915_bib118","doi-asserted-by":"crossref","first-page":"17574","DOI":"10.1038\/s41598-018-35687-8","article-title":"A\u00a0small molecule ApoE4-targeted therapeutic candidate that normalizes sirtuin 1 levels and improves cognition in an Alzheimer\u2019s disease mouse model","volume":"8","author":"Campagna","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejmech.2020.112915_bib119","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1093\/hmg\/ddt402","article-title":"Acetylation of the KXGS motifs in tau is a critical determinant in modulation of tau aggregation and clearance","volume":"23","author":"Cook","year":"2014","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.ejmech.2020.112915_bib120","doi-asserted-by":"crossref","first-page":"15277","DOI":"10.1074\/jbc.M117.794602","article-title":"An acetylation-phosphorylation switch that regulates tau aggregation propensity and function","volume":"292","author":"Carlomagno","year":"2017","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ejmech.2020.112915_bib121","doi-asserted-by":"crossref","DOI":"10.1111\/acel.13081","article-title":"Acetylation changes tau interactome to degrade tau in Alzheimer\u2019s disease animal and organoid models","volume":"19","author":"Choi","year":"2020","journal-title":"Aging Cell"},{"key":"10.1016\/j.ejmech.2020.112915_bib122","author":"US National Library of Medicine"},{"key":"10.1016\/j.ejmech.2020.112915_bib123","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1021\/acschemneuro.8b00405","article-title":"Structure-based drug designing recommends HDAC6 inhibitors to attenuate microtubule-associated tau-pathogenesis","volume":"10","author":"Zeb","year":"2019","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.ejmech.2020.112915_bib124","doi-asserted-by":"crossref","first-page":"E11148","DOI":"10.1073\/pnas.1805436115","article-title":"Inhibition of HDAC3 reverses Alzheimer\u2019s disease-related pathologies in\u00a0vitro and in the 3xTg-AD mouse model","volume":"115","author":"Janczura","year":"2018","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ejmech.2020.112915_bib125","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1038\/nchembio.797","article-title":"Increasing O-GlcNAc slows neurodegeneration and stabilizes tau against aggregation","volume":"8","author":"Yuzwa","year":"2012","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.ejmech.2020.112915_bib126","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1111\/j.1432-1033.1991.tb15976.x","article-title":"N-acetylglucosaminono-1,5-lactone oxime and the corresponding (phenylcarbamoyl)oxime. Novel and potent inhibitors of beta-N-acetylglucosaminidase","volume":"197","author":"Horsch","year":"1991","journal-title":"Eur. J. Biochem."},{"key":"10.1016\/j.ejmech.2020.112915_bib127","doi-asserted-by":"crossref","first-page":"10804","DOI":"10.1073\/pnas.0400348101","article-title":"O-GlcNAcylation regulates phosphorylation of tau: a mechanism involved in Alzheimer\u2019s disease","volume":"101","author":"Liu","year":"2004","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ejmech.2020.112915_bib128","doi-asserted-by":"crossref","first-page":"10059","DOI":"10.1021\/acs.jmedchem.9b01668","article-title":"Sugar kick prevents memory impairment","volume":"62","author":"Rudrawar","year":"2019","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2020.112915_bib129","doi-asserted-by":"crossref","first-page":"6804","DOI":"10.1021\/ja960826u","article-title":"NAG-thiazoline, an N-Acetyl-\u03b2-hexosaminidase inhibitor that implicates Acetamido participation","volume":"118","author":"Knapp","year":"1996","journal-title":"J.\u00a0Am. Chem. Soc."},{"key":"10.1016\/j.ejmech.2020.112915_bib130","doi-asserted-by":"crossref","first-page":"25313","DOI":"10.1074\/jbc.M413819200","article-title":"O-GlcNAcase uses substrate-assisted catalysis: kinetic analysis and development of highly selective mechanism-inspired inhibitors","volume":"280","author":"Macauley","year":"2005","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ejmech.2020.112915_bib131","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/j.chembiol.2010.07.005","article-title":"Elevation of Global O-GlcNAc in rodents using a selective O-GlcNAcase inhibitor does not cause insulin resistance or perturb glucohomeostasis","volume":"17","author":"Macauley","year":"2010","journal-title":"Chem. Biol."},{"key":"10.1016\/j.ejmech.2020.112915_bib132","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1038\/nchembio.96","article-title":"A\u00a0potent mechanism-inspired O-GlcNAcase inhibitor that blocks phosphorylation of tau in\u00a0vivo","volume":"4","author":"Yuzwa","year":"2008","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.ejmech.2020.112915_bib133","article-title":"Differential effects of an O-GlcNAcase inhibitor on tau phosphorylation","volume":"7","author":"Yu","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.ejmech.2020.112915_bib134","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.neuropharm.2013.11.025","article-title":"Increased O-GlcNAcylation reduces pathological tau without affecting its normal phosphorylation in a mouse model of tauopathy","volume":"79","author":"Graham","year":"2014","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.ejmech.2020.112915_bib135","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s13024-017-0181-0","article-title":"Inhibition of O-GlcNAcase leads to elevation of O-GlcNAc tau and reduction of tauopathy and cerebrospinal fluid tau in rTg4510 mice","volume":"12","author":"Hastings","year":"2017","journal-title":"Mol. Neurodegener."},{"key":"10.1016\/j.ejmech.2020.112915_bib136","article-title":"Early intervention of tau pathology prevents behavioral changes in the rTg4510 mouse model of tauopathy","volume":"13","author":"Wang","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.ejmech.2020.112915_bib137","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1021\/acschemneuro.8b00015","article-title":"Pharmacological inhibition of O-GlcNAcase enhances autophagy in brain through an mTOR-independent pathway","volume":"9","author":"Zhu","year":"2018","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.ejmech.2020.112915_bib138","doi-asserted-by":"crossref","first-page":"10062","DOI":"10.1021\/acs.jmedchem.9b01090","article-title":"Discovery of MK-8719, a potent O-GlcNAcase inhibitor as a potential treatment for tauopathies","volume":"62","author":"Selnick","year":"2019","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2020.112915_bib139","doi-asserted-by":"crossref","first-page":"P261","DOI":"10.1016\/j.jalz.2016.06.469","article-title":"Early clinical results and preclinical validation of the O-GlcNAcase (OGA) inhibitor MK-8719 as a novel therapeutic for the treatment of tauopathies","volume":"12","author":"Smith","year":"2016","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.ejmech.2020.112915_bib140","doi-asserted-by":"crossref","first-page":"P1028","DOI":"10.1016\/j.jalz.2016.06.2125","article-title":"Pharmacokinetics and pharmacodynamics to support clinical studies of MK-8719: an O-GlcNAcase inhibitor for progressive supranuclear palsy","volume":"12","author":"Sandhu","year":"2016","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.ejmech.2020.112915_bib141","series-title":"Alectos Therapeutics announces FDA orphan drug designation for MK-8719: an investigational small-molecule OGA inhibitor for treatment of progressive supranuclear palsy","year":"2016"},{"key":"10.1016\/j.ejmech.2020.112915_bib145","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.neurobiolaging.2010.09.008","article-title":"Cleavage of Tau by calpain in Alzheimer\u2019s disease: the quest for the toxic 17 kD fragment","volume":"32","author":"Garg","year":"2011","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.ejmech.2020.112915_bib146","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1006\/bbrc.1994.1759","article-title":"Proteolytic degradation of microtubule associated protein tau by thrombin","volume":"201","author":"Olesen","year":"1994","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.ejmech.2020.112915_bib147","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1007\/s11064-010-0395-9","article-title":"A\u00a0novel approach for characterization of cathepsin D protease and its effect on tau and beta-amyloid proteins","volume":"36","author":"Malik","year":"2011","journal-title":"Neurochem. Res."},{"key":"10.1016\/j.ejmech.2020.112915_bib148","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1093\/hmg\/ddr065","article-title":"Puromycin-sensitive aminopeptidase (PSA\/NPEPPS) impedes development of neuropathology in hPSA\/TAU(P301L) double-transgenic mice","volume":"20","author":"Kudo","year":"2011","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.ejmech.2020.112915_bib149","doi-asserted-by":"crossref","first-page":"20931","DOI":"10.1074\/jbc.M111.316232","article-title":"Human high temperature requirement serine protease A1 (HTRA1) degrades tau protein aggregates","volume":"287","author":"Tennstaedt","year":"2012","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ejmech.2020.112915_bib150","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2013.00122","article-title":"Tau clearance mechanisms and their possible role in the pathogenesis of Alzheimer disease","volume":"4","author":"Chesser","year":"2013","journal-title":"Front. Neurol."},{"key":"10.1016\/j.ejmech.2020.112915_bib151","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1078\/0065-1281-00601","article-title":"The history of Z-VAD-FMK, a tool for understanding the significance of caspase inhibition","volume":"103","author":"Van Noorden","year":"2001","journal-title":"Acta Histochem."},{"key":"10.1016\/j.ejmech.2020.112915_bib152","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.3233\/JAD-150960","article-title":"Halting of caspase activity protects tau from MC1-conformational change and aggregation","volume":"54","author":"Mead","year":"2016","journal-title":"J.\u00a0Alzheimers Dis."},{"key":"10.1016\/j.ejmech.2020.112915_bib153","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/sj.cdd.4402044","article-title":"Broad-spectrum caspase inhibitors: from myth to reality?","volume":"14","author":"Chauvier","year":"2007","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.ejmech.2020.112915_bib154","first-page":"1","article-title":"Inhibition of apoptosis and efficacy of Pan caspase inhibitor, Q-VD-OPh, in models of human disease","volume":"8","author":"Keoni","year":"2015","journal-title":"J.\u00a0Cell Death"},{"key":"10.1016\/j.ejmech.2020.112915_bib155","first-page":"300","article-title":"Caspase activation in transgenic mice with Alzheimer-like pathology: results from a pilot study utilizing the caspase inhibitor, Q-VD-OPh","volume":"2","author":"Rohn","year":"2009","journal-title":"Int. J. Clin. Exp. Med."},{"key":"10.1016\/j.ejmech.2020.112915_bib156","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1096\/fj.08-113795","article-title":"Minocycline reduces the development of abnormal tau species in models of Alzheimer\u2019s disease","volume":"23","author":"Noble","year":"2009","journal-title":"Faseb. J."},{"key":"10.1016\/j.ejmech.2020.112915_bib157","doi-asserted-by":"crossref","first-page":"e167","DOI":"10.1038\/cddis.2011.50","article-title":"Astrocytes are important mediators of Abeta-induced neurotoxicity and tau phosphorylation in primary culture","volume":"2","author":"Garwood","year":"2011","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.ejmech.2020.112915_bib158","series-title":"Alzheimer Disease Efficacy Trialist, Minocycline at 2 Different Dosages vs Placebo for Patients with Mild Alzheimer Disease: A Randomized Clinical Trial, JAMA Neurol. 1","first-page":"164","volume":"vol. 77","author":"Howard","year":"2020"},{"key":"10.1016\/j.ejmech.2020.112915_bib159","doi-asserted-by":"crossref","first-page":"11213","DOI":"10.1073\/pnas.93.20.11213","article-title":"Selective inhibition of Alzheimer disease-like tau aggregation by phenothiazines","volume":"93","author":"Wischik","year":"1996","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ejmech.2020.112915_bib160","doi-asserted-by":"crossref","first-page":"7614","DOI":"10.1074\/jbc.M408714200","article-title":"Inhibition of heparin-induced tau filament formation by phenothiazines, polyphenols, and porphyrins","volume":"280","author":"Taniguchi","year":"2005","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ejmech.2020.112915_bib161","doi-asserted-by":"crossref","first-page":"11024","DOI":"10.1074\/jbc.M112.436006","article-title":"Aminothienopyridazines and methylene blue affect Tau fibrillization via cysteine oxidation","volume":"288","author":"Crowe","year":"2013","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ejmech.2020.112915_bib162","doi-asserted-by":"crossref","first-page":"705","DOI":"10.3233\/JAD-142874","article-title":"Tau aggregation inhibitor therapy: an exploratory phase 2 study in mild or moderate Alzheimer\u2019s disease","volume":"44","author":"Wischik","year":"2015","journal-title":"J.\u00a0Alzheimers Dis."},{"key":"10.1016\/j.ejmech.2020.112915_bib164","doi-asserted-by":"crossref","first-page":"435","DOI":"10.3233\/JAD-170560","article-title":"Potential of low dose leuco-methylthioninium Bis(hydromethanesulphonate) (LMTM) monotherapy for treatment of mild Alzheimer\u2019s disease: cohort analysis as modified primary outcome in a phase III clinical trial","volume":"61","author":"Wilcock","year":"2018","journal-title":"J.\u00a0Alzheimers Dis."},{"key":"10.1016\/j.ejmech.2020.112915_bib165","author":"US National Library of Medicine"},{"key":"10.1016\/j.ejmech.2020.112915_bib166","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/978-0-387-46401-5_8","article-title":"Neuroprotective effects of curcumin","volume":"595","author":"Cole","year":"2007","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.ejmech.2020.112915_bib167","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.1001080","article-title":"Towards a pharmacophore for amyloid","volume":"9","author":"Landau","year":"2011","journal-title":"PLoS Biol."},{"key":"10.1016\/j.ejmech.2020.112915_bib168","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1007\/s12035-010-8137-1","article-title":"Why pleiotropic interventions are needed for Alzheimer\u2019s disease","volume":"41","author":"Frautschy","year":"2010","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.ejmech.2020.112915_bib169","author":"US National Library of Medicine"},{"key":"10.1016\/j.ejmech.2020.112915_bib170","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1002\/ptr.6257","article-title":"Curcumin intervention for cognitive function in different types of people: a systematic review and meta-analysis","volume":"33","author":"Zhu","year":"2019","journal-title":"Phytother Res."},{"key":"10.1016\/j.ejmech.2020.112915_bib171","doi-asserted-by":"crossref","first-page":"5024","DOI":"10.1016\/j.bmcl.2016.08.092","article-title":"Design and synthesis of curcumin derivatives as tau and amyloid \u03b2 dual aggregation inhibitors","volume":"26","author":"Okuda","year":"2016","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2020.112915_bib172","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1002\/cmdc.200700218","article-title":"Curcumin-derived pyrazoles and isoxazoles: swiss army knives or blunt tools for Alzheimer\u2019s disease?","volume":"3","author":"Narlawar","year":"2008","journal-title":"ChemMedChem"},{"key":"10.1016\/j.ejmech.2020.112915_bib173","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1021\/cn200088r","article-title":"Clicked\" sugar-curcumin conjugate: modulator of amyloid-\u03b2 and tau peptide aggregation at ultralow concentrations","volume":"2","author":"Dolai","year":"2011","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.ejmech.2020.112915_bib174","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.1021\/bi036094h","article-title":"Ligand-dependent inhibition and reversal of tau filament formation","volume":"43","author":"Chirita","year":"2004","journal-title":"Biochemistry"},{"key":"10.1016\/j.ejmech.2020.112915_bib175","doi-asserted-by":"crossref","first-page":"10227","DOI":"10.1021\/bi050387o","article-title":"Cyanine dye N744 inhibits tau fibrillization by blocking filament extension: implications for the treatment of tauopathic neurodegenerative diseases","volume":"44","author":"Necula","year":"2005","journal-title":"Biochemistry"},{"issue":"48","key":"10.1016\/j.ejmech.2020.112915_bib176","doi-asserted-by":"crossref","first-page":"9215","DOI":"10.1002\/anie.200704051","article-title":"Rhodanine-based Tau aggregation inhibitors in cell models of tauopathy","volume":"46","author":"Bulic","year":"2007","journal-title":"Angew. Chem. Int. Ed."},{"key":"10.1016\/j.ejmech.2020.112915_bib177","doi-asserted-by":"crossref","first-page":"3739","DOI":"10.1021\/jm100138f","article-title":"Discovery of brain-penetrant, orally bioavailable aminothienopyridazine inhibitors of tau aggregation","volume":"53","author":"Ballatore","year":"2010","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2020.112915_bib178","first-page":"4451","article-title":"Aminothienopyridazine inhibitors of tau aggregation: evaluation of structure-activity relationship leads to selection of candidates with desirable in\u00a0vivo properties, Bioorg","volume":"20","author":"Ballatore","year":"2012","journal-title":"Med. Chem."},{"key":"10.1016\/j.ejmech.2020.112915_bib179","doi-asserted-by":"crossref","first-page":"21","DOI":"10.3233\/JAD-122113","article-title":"Interaction of cinnamaldehyde and epicatechin with tau: implications of beneficial effects in modulating Alzheimer\u2019s disease pathogenesis","volume":"36","author":"George","year":"2013","journal-title":"J.\u00a0Alzheim. Dis."},{"key":"10.1016\/j.ejmech.2020.112915_bib180","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejmech.2014.07.095","article-title":"Development of dual targeting inhibitors against aggregations of amyloid-\u03b2 and tau protein","volume":"85","author":"Fuse","year":"2014","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2020.112915_bib181","first-page":"485","article-title":"Inhibitory effect of corcin on aggregation of 1N\/4R human tau protein in\u00a0vitro, Iran","volume":"18","author":"Karakani","year":"2015","journal-title":"J.\u00a0Basic Med. Sci."},{"key":"10.1016\/j.ejmech.2020.112915_bib182","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ejps.2016.04.012","article-title":"Identifying GSK-3\u03b2 kinase inhibitors of Alzheimer\u2019s disease: virtual screening, enzyme, and cell assays","volume":"89","author":"Lin","year":"2016","journal-title":"Eur. J. Pharmaceut. Sci."},{"key":"10.1016\/j.ejmech.2020.112915_bib183","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1159\/000448518","article-title":"Cl-NQTrp alleviates tauopathy symptoms in a model organism through the inhibition of tau aggregation-engendered toxicity","volume":"17","author":"Frenkel-Pinter","year":"2017","journal-title":"Neurodegener. Dis."},{"key":"10.1016\/j.ejmech.2020.112915_bib184","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1021\/acschembio.7b00489","article-title":"Small molecule enhancement of 20S proteasome activity targets intrinsically disordered proteins","volume":"12","author":"Jones","year":"2017","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.ejmech.2020.112915_bib185","doi-asserted-by":"crossref","first-page":"4214","DOI":"10.1021\/acs.biochem.8b00579","article-title":"Small molecule modulation of proteasome assembly","volume":"57","author":"Njomen","year":"2018","journal-title":"Biochemistry"},{"key":"10.1016\/j.ejmech.2020.112915_bib186","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/nature09299","article-title":"Enhancement of proteasome activity by a small-molecule inhibitor of USP14","volume":"467","author":"Lee","year":"2010","journal-title":"Nature"},{"issue":"R110","key":"10.1016\/j.ejmech.2020.112915_bib187","article-title":"Trimming of ubiquitin chains by proteasome-associated deubiquitinating enzymes","volume":"10","author":"Lee","year":"2011","journal-title":"Mol. Cell. Proteomics"},{"key":"10.1016\/j.ejmech.2020.112915_bib188","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1016\/j.bbadis.2017.03.017","article-title":"Neurotoxic mechanisms by which the USP14 inhibitor IU1 depletes ubiquitinated proteins and Tau in rat cerebral cortical neurons: relevance to Alzheimer\u2019s disease","volume":"1863","author":"Kiprowska","year":"2017","journal-title":"Biochim. Biophys. Acta (BBA) - Mol. Basis Dis."},{"key":"10.1016\/j.ejmech.2020.112915_bib189","doi-asserted-by":"crossref","first-page":"19209","DOI":"10.1074\/jbc.M117.815126","article-title":"An inhibitor of the proteasomal deubiquitinating enzyme USP14 induces tau elimination in cultured neurons","volume":"292","author":"Boselli","year":"2017","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ejmech.2020.112915_bib190","doi-asserted-by":"crossref","first-page":"E7176","DOI":"10.1073\/pnas.1522332112","article-title":"cAMP-induced phosphorylation of 26S proteasomes on Rpn6\/PSMD11 enhances their activity and the degradation of misfolded proteins","volume":"112","author":"Lokireddy","year":"2015","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ejmech.2020.112915_bib191","doi-asserted-by":"crossref","first-page":"14220","DOI":"10.1073\/pnas.2003277117","article-title":"cGMP via PKG activates 26S proteasomes and enhances degradation of proteins, including ones that cause neurodegenerative diseases","volume":"117","author":"VerPlank","year":"2020","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ejmech.2020.112915_bib192","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/0028-3908(83)90239-3","article-title":"Potential antidepressant activity of rolipram and other selective cyclic adenosine 3\u2019,5\u2019-monophosphate phosphodiesterase inhibitors","volume":"22","author":"Wachtel","year":"1983","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.ejmech.2020.112915_bib193","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1038\/nm.4011","article-title":"Tau-driven 26S proteasome impairment and cognitive dysfunction can be prevented early in disease by activating cAMP-PKA signaling","volume":"22","author":"Myeku","year":"2016","journal-title":"Nat. Med."},{"key":"10.1016\/j.ejmech.2020.112915_bib194","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/nbt.1598","article-title":"Design of phosphodiesterase 4D (PDE4D) allosteric modulators for enhancing cognition with improved safety","volume":"28","author":"Burgin","year":"2010","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ejmech.2020.112915_bib195","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1124\/jpet.119.259986","article-title":"Protection from amyloid beta peptide-induced memory, biochemical, and morphological deficits by a phosphodiesterase-4D allosteric inhibitor","volume":"371","author":"Cui","year":"2019","journal-title":"J.\u00a0Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.ejmech.2020.112915_bib196","author":"US National Library of Medicine"},{"key":"10.1016\/j.ejmech.2020.112915_bib197","author":"US National Library of Medicine"},{"key":"10.1016\/j.ejmech.2020.112915_bib199","author":"US National Library of Medicine"},{"key":"10.1016\/j.ejmech.2020.112915_bib201","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.trsl.2017.11.004","article-title":"Cilostazol, a phosphodiesterase 3 inhibitor, activates proteasome-mediated proteolysis and attenuates tauopathy and cognitive decline","volume":"193","author":"Schaler","year":"2018","journal-title":"Transl. Res."},{"key":"10.1016\/j.ejmech.2020.112915_bib202","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1097\/JGP.0b013e31819431ea","article-title":"A\u00a0combination therapy of donepezil and cilostazol for patients with moderate Alzheimer disease: pilot follow-up study","volume":"17","author":"Arai","year":"2009","journal-title":"Am. J. Geriatr. Psychiatr."},{"key":"10.1016\/j.ejmech.2020.112915_bib203","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1111\/j.1447-0594.2012.00866.x","article-title":"Effects of cilostazol on cognition and regional cerebral blood flow in patients with Alzheimer\u2019s disease and cerebrovascular disease: a pilot study","volume":"13","author":"Sakurai","year":"2013","journal-title":"Geriatr. Gerontol. Int."},{"key":"10.1016\/j.ejmech.2020.112915_bib204","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1111\/psyg.12021","article-title":"Cilostazol improves cognitive function in patients with mild cognitive impairment: a retrospective analysis","volume":"13","author":"Taguchi","year":"2013","journal-title":"Psychogeriatrics"},{"key":"10.1016\/j.ejmech.2020.112915_bib205","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0089516","article-title":"Cilostazol add-on therapy in patients with mild dementia receiving donepezil: a retrospective study","volume":"9","author":"Ihara","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.ejmech.2020.112915_bib206","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s12883-017-0800-y","article-title":"Cilostazol as an add-on therapy for patients with Alzheimer\u2019s disease in Taiwan: a case control study","volume":"17","author":"Tai","year":"2017","journal-title":"BMC Neurol."},{"key":"10.1016\/j.ejmech.2020.112915_bib207","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1007\/s13311-017-0512-4","article-title":"Cilostazol use is associated with reduced risk of dementia: a nationwide cohort study","volume":"14","author":"Tai","year":"2017","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.ejmech.2020.112915_bib208","author":"US National Library of Medicine"},{"key":"10.1016\/j.ejmech.2020.112915_bib209","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1007\/s13311-018-00708-x","article-title":"Efficacy of cilostazol administration in Alzheimer\u2019s disease patients with white matter lesions: a positron-emission tomography study","volume":"16","author":"Lee","year":"2019","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.ejmech.2020.112915_bib211","doi-asserted-by":"crossref","first-page":"91","DOI":"10.3233\/ADR-200166","article-title":"Sildenafil for the treatment of Alzheimer\u2019s disease: a systematic review","volume":"4","author":"Sanders","year":"2020","journal-title":"J.\u00a0Alzheimers Dis. Rep."},{"key":"10.1016\/j.ejmech.2020.112915_bib212","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.3233\/JAD-161006","article-title":"Sildenafil improves vascular and metabolic function in patients with Alzheimer\u2019s disease","volume":"60","author":"Sheng","year":"2017","journal-title":"J.\u00a0Alzheimers Dis."},{"key":"10.1016\/j.ejmech.2020.112915_bib213","doi-asserted-by":"crossref","first-page":"163","DOI":"10.3233\/JAD-190128","article-title":"A\u00a0pilot study of changes in medial temporal lobe fractional Amplitude of low frequency fluctuations after sildenafil administration in patients with Alzheimer\u2019s disease","volume":"70","author":"Samudra","year":"2019","journal-title":"J.\u00a0Alzheimers Dis."},{"key":"10.1016\/j.ejmech.2020.112915_bib214","doi-asserted-by":"crossref","DOI":"10.1002\/bies.201700247","article-title":"PROTACs: an emerging targeting technique for protein degradation in drug discovery","volume":"40","author":"Gu","year":"2018","journal-title":"Bioessays"},{"key":"10.1016\/j.ejmech.2020.112915_bib215","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.chembiol.2016.02.016","article-title":"Specific knockdown of endogenous tau protein by peptide-directed ubiquitin-proteasome degradation","volume":"23","author":"Chu","year":"2016","journal-title":"Cell Chem. Biol."},{"key":"10.1016\/j.ejmech.2020.112915_bib216","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.ejmech.2018.01.063","article-title":"Discovery of a Keap1-dependent peptide PROTAC to knockdown Tau by ubiquitination-proteasome degradation pathway","volume":"146","author":"Lu","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2020.112915_bib217","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.45457","article-title":"Targeted degradation of aberrant tau in frontotemporal dementia patient-derived neuronal cell models","volume":"8","author":"Silva","year":"2019","journal-title":"eLife"},{"key":"10.1016\/j.ejmech.2020.112915_bib218","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1021\/acsmedchemlett.9b00083","article-title":"Treatment of Alzheimer\u2019s by PROTAC-tau protein degradation","volume":"10","author":"Kargbo","year":"2019","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2020.112915_bib219","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1093\/hmg\/ddi458","article-title":"Rapamycin alleviates toxicity of different aggregate-prone proteins","volume":"15","author":"Berger","year":"2006","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.ejmech.2020.112915_bib220","doi-asserted-by":"crossref","first-page":"13107","DOI":"10.1074\/jbc.M110.100420","article-title":"Molecular interplay between mammalian target of rapamycin (mTOR), amyloid-beta, and Tau: effects on cognitive impairments","volume":"285","author":"Caccamo","year":"2010","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ejmech.2020.112915_bib221","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0025416","article-title":"Inducing autophagy by rapamycin before, but not after, the formation of plaques and tangles ameliorates cognitive deficits","volume":"6","author":"Majumder","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.ejmech.2020.112915_bib222","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0062459","article-title":"Rapamycin attenuates the progression of tau pathology in P301S tau transgenic mice","volume":"8","author":"Ozcelik","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.ejmech.2020.112915_bib223","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1111\/acel.12057","article-title":"mTOR regulates tau phosphorylation and degradation: implications for Alzheimer\u2019s disease and other tauopathies","volume":"12","author":"Caccamo","year":"2013","journal-title":"Aging Cell"},{"key":"10.1016\/j.ejmech.2020.112915_bib225","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.neuropharm.2014.05.032","article-title":"Temsirolimus attenuates tauopathy in\u00a0vitro and in\u00a0vivo by targeting tau hyperphosphorylation and autophagic clearance","volume":"85","author":"Jiang","year":"2014","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.ejmech.2020.112915_bib226","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.3233\/JAD-142097","article-title":"Rapamycin ester analog CCI-779\/Temsirolimus alleviates tau pathology and improves motor deficit in mutant tau transgenic mice","volume":"44","author":"Frederick","year":"2015","journal-title":"J.\u00a0Alzheimers Dis."},{"key":"10.1016\/j.ejmech.2020.112915_bib227","first-page":"2291","article-title":"Autophagic degradation of tau in primary neurons and its enhancement by trehalose, Neurobiol","volume":"33","author":"Kruger","year":"2012","journal-title":"Aging"},{"key":"10.1016\/j.ejmech.2020.112915_bib228","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.nbd.2010.05.014","article-title":"Trehalose ameliorates dopaminergic and tau pathology in parkin deleted\/tau overexpressing mice through autophagy activation","volume":"39","author":"Rodriguez-Navarro","year":"2010","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.ejmech.2020.112915_bib229","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1093\/brain\/aws143","article-title":"Stimulation of autophagy reduces neurodegeneration in a mouse model of human tauopathy","volume":"135","author":"Schaeffer","year":"2012","journal-title":"Brain"},{"key":"10.1016\/j.ejmech.2020.112915_bib230","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1083\/jcb.200504035","article-title":"Lithium induces autophagy by inhibiting inositol monophosphatase","volume":"170","author":"Sarkar","year":"2005","journal-title":"J.\u00a0Cell Biol."},{"key":"10.1016\/j.ejmech.2020.112915_bib231","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.nbd.2011.12.050","article-title":"Long-term oral lithium treatment attenuates motor disturbance in tauopathy model mice: implications of autophagy promotion","volume":"46","author":"Shimada","year":"2012","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.ejmech.2020.112915_bib232","doi-asserted-by":"crossref","first-page":"56","DOI":"10.3389\/fncel.2013.00056","article-title":"Methylene blue induces macroautophagy through 5\u2019 adenosine monophosphate-activated protein kinase pathway to protect neurons from serum deprivation","volume":"7","author":"Xie","year":"2013","journal-title":"Front. Cell. Neurosci."},{"key":"10.1016\/j.ejmech.2020.112915_bib233","doi-asserted-by":"crossref","first-page":"609","DOI":"10.4161\/auto.19048","article-title":"Methylthioninium chloride (methylene blue) induces autophagy and attenuates tauopathy in\u00a0vitro and in\u00a0vivo","volume":"8","author":"Congdon","year":"2012","journal-title":"Autophagy"},{"key":"10.1016\/j.ejmech.2020.112915_bib234","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/1750-1326-5-45","article-title":"Phenothiazine-mediated rescue of cognition in tau transgenic mice requires neuroprotection and reduced soluble tau burden","volume":"5","author":"O\u2019Leary","year":"2010","journal-title":"Mol. Neurodegener."},{"key":"10.1016\/j.ejmech.2020.112915_bib235","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1016\/j.clinthera.2008.11.014","article-title":"Nilotinib: a second-generation tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia","volume":"30","author":"Deremer","year":"2008","journal-title":"Clin. Therapeut."},{"key":"10.1016\/j.ejmech.2020.112915_bib236","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.jns.2018.06.005","article-title":"Tau clearance improves astrocytic function and brain glutamate-glutamine cycle","volume":"391","author":"Hebron","year":"2018","journal-title":"J.\u00a0Neurol. Sci."},{"key":"10.1016\/j.ejmech.2020.112915_bib237","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1002\/ana.25775","article-title":"Nilotinib effects on safety, tolerability, and biomarkers in Alzheimer\u2019s disease","volume":"88","author":"Turner","year":"2020","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.ejmech.2020.112915_bib238","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1111\/jnc.14109","article-title":"Pimozide reduces toxic forms of tau in TauC3 mice via 5\u2019 adenosine monophosphate-activated protein kinase-mediated autophagy","volume":"142","author":"Kim","year":"2017","journal-title":"J.\u00a0Neurochem."},{"key":"10.1016\/j.ejmech.2020.112915_bib239","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aat3005","article-title":"A\u00a0farnesyltransferase inhibitor activates lysosomes and reduces tau pathology in mice with tauopathy","volume":"11","author":"Hernandez","year":"2019","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ejmech.2020.112915_bib240","doi-asserted-by":"crossref","first-page":"4869","DOI":"10.1074\/jbc.M305838200","article-title":"CHIP-Hsc70 complex ubiquitinates phosphorylated tau and enhances cell survival","volume":"279","author":"Shimura","year":"2004","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ejmech.2020.112915_bib241","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1093\/hmg\/ddh083","article-title":"CHIP and Hsp70 regulate tau ubiquitination, degradation and aggregation","volume":"13","author":"Petrucelli","year":"2004","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.ejmech.2020.112915_bib242","first-page":"239164","article-title":"Heat shock proteins at the crossroads between cancer and Alzheimer\u2019s disease","volume":"2014","author":"Wang","year":"2014","journal-title":"BioMed Res. Int."},{"key":"10.1016\/j.ejmech.2020.112915_bib243","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/0968-0004(90)90019-8","article-title":"Peptide sequences that target cytosolic proteins for lysosomal proteolysis","volume":"15","author":"Dice","year":"1990","journal-title":"Trends Biochem. Sci."},{"key":"10.1016\/j.ejmech.2020.112915_bib244","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/S0070-2153(05)73007-6","article-title":"Chaperone-mediated autophagy in aging and disease","volume":"73","author":"Massey","year":"2006","journal-title":"Curr. Top. Dev. Biol."},{"key":"10.1016\/j.ejmech.2020.112915_bib245","doi-asserted-by":"crossref","first-page":"4153","DOI":"10.1093\/hmg\/ddp367","article-title":"Tau fragmentation, aggregation and clearance: the dual role of lysosomal processing","volume":"18","author":"Wang","year":"2009","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.ejmech.2020.112915_bib246","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.ab.2007.08.020","article-title":"High-throughput screen for small molecules that modulate the ATPase activity of the molecular chaperone DnaK","volume":"372","author":"Chang","year":"2008","journal-title":"Anal. Biochem."},{"key":"10.1016\/j.ejmech.2020.112915_bib247","first-page":"43","article-title":"Hsp70 ATPase modulators as therapeutics for Alzheimer\u2019s and other neurodegenerative diseases","volume":"2","author":"Jinwal","year":"2010","journal-title":"Mol. Cell. Pharmacol."},{"key":"10.1016\/j.ejmech.2020.112915_bib248","doi-asserted-by":"crossref","first-page":"12079","DOI":"10.1523\/JNEUROSCI.3345-09.2009","article-title":"Chemical manipulation of hsp70 ATPase activity regulates tau stability","volume":"29","author":"Jinwal","year":"2009","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.ejmech.2020.112915_bib249","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.biopsych.2013.02.027","article-title":"Allosteric heat shock protein 70 inhibitors rapidly rescue synaptic plasticity deficits by reducing aberrant tau","volume":"74","author":"Abisambra","year":"2013","journal-title":"Biol. Psychiatr."},{"key":"10.1016\/j.ejmech.2020.112915_bib250","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1021\/cn300210g","article-title":"Synthesis and initial evaluation of YM-08, a blood-brain barrier permeable derivative of the heat shock protein 70 (Hsp70) inhibitor MKT-077, which reduces tau levels","volume":"4","author":"Miyata","year":"2013","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.ejmech.2020.112915_bib251","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1016\/j.chembiol.2016.04.014","article-title":"Stabilizing the hsp70-tau complex promotes turnover in models of tauopathy","volume":"23","author":"Young","year":"2016","journal-title":"Cell Chem. Biol."},{"key":"10.1016\/j.ejmech.2020.112915_bib252","doi-asserted-by":"crossref","first-page":"3973","DOI":"10.1093\/hmg\/ddx284","article-title":"Enhanced tau pathology via RanBP9 and Hsp90\/Hsc70 chaperone complexes","volume":"26","author":"Woo","year":"2017","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.ejmech.2020.112915_bib253","doi-asserted-by":"crossref","first-page":"48","DOI":"10.3389\/fphar.2018.00048","article-title":"Heat shock cognate 70 inhibitor, VER-155008, reduces memory deficits and axonal degeneration in a mouse model of Alzheimer\u2019s disease","volume":"9","author":"Yang","year":"2018","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejmech.2020.112915_bib254","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1021\/acschembio.6b00223","article-title":"Inhibition of both Hsp70 activity and tau aggregation in\u00a0vitro best predicts tau lowering activity of small molecules","volume":"11","author":"Martin","year":"2016","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.ejmech.2020.112915_bib255","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1111\/j.1745-7270.2005.00069.x","article-title":"Heat shock protein 90 indirectly regulates ERK activity by affecting Raf protein metabolism","volume":"37","author":"Dou","year":"2005","journal-title":"Acta Biochim. Biophys. Sin."},{"key":"10.1016\/j.ejmech.2020.112915_bib256","doi-asserted-by":"crossref","first-page":"9511","DOI":"10.1073\/pnas.0701055104","article-title":"Roles of heat-shock protein 90 in maintaining and facilitating the neurodegenerative phenotype in tauopathies","volume":"104","author":"Luo","year":"2007","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ejmech.2020.112915_bib257","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1096\/fj.05-5343fje","article-title":"HSP induction mediates selective clearance of tau phosphorylated at proline-directed Ser\/Thr sites but not KXGS (MARK) sites","volume":"20","author":"Dickey","year":"2006","journal-title":"Faseb. J."},{"key":"10.1016\/j.ejmech.2020.112915_bib258","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1021\/jm0503087","article-title":"Orally active purine-based inhibitors of the heat shock protein 90","volume":"49","author":"Biamonte","year":"2006","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2020.112915_bib259","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1172\/JCI29715","article-title":"The high-affinity HSP90-CHIP complex recognizes and selectively degrades phosphorylated tau client proteins","volume":"117","author":"Dickey","year":"2007","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.ejmech.2020.112915_bib260","doi-asserted-by":"crossref","first-page":"51","DOI":"10.3389\/fmolb.2018.00051","article-title":"Dihydropyridines Allosterically modulate Hsp90 providing a novel mechanism for heat shock protein Co-induction and neuroprotection","volume":"5","author":"Roe","year":"2018","journal-title":"Front. Mol. Biosci."},{"key":"10.1016\/j.ejmech.2020.112915_bib261","doi-asserted-by":"crossref","first-page":"557","DOI":"10.3233\/JAD-150860","article-title":"Dihydropyridine derivatives modulate heat shock responses and have a neuroprotective effect in a transgenic mouse model of Alzheimer\u2019s disease","volume":"53","author":"Kasza","year":"2016","journal-title":"J.\u00a0Alzheimers Dis."},{"key":"10.1016\/j.ejmech.2020.112915_bib262","doi-asserted-by":"crossref","first-page":"35381","DOI":"10.1074\/jbc.M109.051532","article-title":"Characterization of celastrol to inhibit hsp90 and cdc37 interaction","volume":"284","author":"Zhang","year":"2009","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ejmech.2020.112915_bib263","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1002\/bab.1633","article-title":"Effects of celastrol on Tau hyperphosphorylation and expression of HSF-1 and HSP70 in SH-SY5Y neuroblastoma cells induced by amyloid-beta peptides","volume":"65","author":"Cao","year":"2018","journal-title":"Biotechnol. Appl. Biochem."},{"key":"10.1016\/j.ejmech.2020.112915_bib264","doi-asserted-by":"crossref","first-page":"6985","DOI":"10.1523\/JNEUROSCI.0746-06.2006","article-title":"Deletion of the ubiquitin ligase CHIP leads to the accumulation, but not the aggregation, of both endogenous phospho- and caspase-3-cleaved tau species","volume":"26","author":"Dickey","year":"2006","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.ejmech.2020.112915_bib265","doi-asserted-by":"crossref","DOI":"10.1002\/mnfr.201800240","article-title":"Sulforaphane upregulates the heat shock protein Co-chaperone CHIP and clears amyloid-beta and tau in a mouse model of Alzheimer\u2019s disease","volume":"62","author":"Lee","year":"2018","journal-title":"Mol. Nutr. Food Res."},{"key":"10.1016\/j.ejmech.2020.112915_bib266","doi-asserted-by":"crossref","first-page":"9707","DOI":"10.1073\/pnas.1707039114","article-title":"Hsp90 activator Aha1 drives production of pathological tau aggregates","volume":"114","author":"Shelton","year":"2017","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ejmech.2020.112915_bib267","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1523\/JNEUROSCI.4815-09.2010","article-title":"The Hsp90 cochaperone, FKBP51, increases Tau stability and polymerizes microtubules","volume":"30","author":"Jinwal","year":"2010","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.ejmech.2020.112915_bib268","doi-asserted-by":"crossref","first-page":"4158","DOI":"10.1172\/JCI69003","article-title":"Accelerated neurodegeneration through chaperone-mediated oligomerization of tau","volume":"123","author":"Blair","year":"2013","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.ejmech.2020.112915_bib269","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/nchembio.1699","article-title":"Selective inhibitors of the FK506-binding protein 51 by induced fit","volume":"11","author":"Gaali","year":"2015","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.ejmech.2020.112915_bib270","doi-asserted-by":"crossref","DOI":"10.1111\/adb.12758","article-title":"The selective FKBP51 inhibitor SAFit2 reduces alcohol consumption and reinstatement of conditioned alcohol effects in mice","volume":"25","author":"Konig","year":"2020","journal-title":"Addiction Biol."},{"key":"10.1016\/j.ejmech.2020.112915_bib271","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1523\/JNEUROSCI.4660-08.2009","article-title":"The cochaperone BAG2 sweeps paired helical filament- insoluble tau from the microtubule","volume":"29","author":"Carrettiero","year":"2009","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.ejmech.2020.112915_bib272","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.neulet.2013.09.008","article-title":"Curcumin-induced upregulation of the anti-tau cochaperone BAG2 in primary rat cortical neurons","volume":"554","author":"Patil","year":"2013","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.ejmech.2020.112915_bib273","doi-asserted-by":"crossref","first-page":"4056","DOI":"10.1074\/jbc.M112.393751","article-title":"Curcumin suppresses soluble tau dimers and corrects molecular chaperone, synaptic, and behavioral deficits in aged human tau transgenic mice","volume":"288","author":"Ma","year":"2013","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ejmech.2020.112915_bib274","doi-asserted-by":"crossref","first-page":"5298","DOI":"10.1016\/j.bmc.2014.07.053","article-title":"Shogaol-huprine hybrids: dual antioxidant and anticholinesterase agents with \u03b2-amyloid and tau anti-aggregating properties","volume":"22","author":"Perez-Areales","year":"2014","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2020.112915_bib275","doi-asserted-by":"crossref","first-page":"6018","DOI":"10.1021\/acs.jmedchem.5b00624","article-title":"Novel levetiracetam derivatives that are effective against the Alzheimer-like phenotype in mice: synthesis, in\u00a0vitro, ex\u00a0vivo, and in\u00a0vivo efficacy studies","volume":"58","author":"Sola","year":"2015","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2020.112915_bib276","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.ejmech.2018.12.063","article-title":"Design, biological evaluation and X-ray crystallography of nanomolar multifunctional ligands targeting simultaneously acetylcholinesterase and glycogen synthase kinase-3","volume":"168","author":"Oukoloff","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2020.112915_bib277","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1021\/acschemneuro.5b00121","article-title":"3,4-Dihydro-1,3,5-triazin-2(1H)-ones as the first dual BACE-1\/GSK-3\u03b2 fragment hits against Alzheimer\u2019s disease","volume":"6","author":"Prati","year":"2015","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.ejmech.2020.112915_bib278","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1021\/acsmedchemlett.8b00507","article-title":"Discovery of the first-in-class GSK-3\u03b2\/HDAC dual inhibitor as disease-modifying agent to combat Alzheimer\u2019s disease","volume":"10","author":"De Simone","year":"2019","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2020.112915_bib279","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1038\/npp.2016.163","article-title":"A\u00a0first-in-class small-molecule that acts as a dual inhibitor of HDAC and PDE5 and that rescues hippocampal synaptic impairment in Alzheimer\u2019s disease mice","volume":"42","author":"Cuadrado-Tejedor","year":"2017","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.ejmech.2020.112915_bib280","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1002\/ddr.21587","article-title":"Natural products and their derivatives as multifunctional ligands against Alzheimer\u2019s disease","volume":"81","author":"Patil","year":"2020","journal-title":"Drug Dev. Res."},{"key":"10.1016\/j.ejmech.2020.112915_bib281","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1021\/acs.jmedchem.5b00894","article-title":"Versatility of the curcumin scaffold: discovery of potent and balanced dual BACE-1 and GSK-3\u03b2 inhibitors","volume":"59","author":"Di Martino","year":"2016","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2020.112915_bib282","doi-asserted-by":"crossref","first-page":"112593","DOI":"10.1016\/j.ejmech.2020.112593","article-title":"Discovery of novel berberine derivatives with balanced cholinesterase and prolyl oligopeptidase inhibition profile","volume":"203","author":"Sobolova","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2020.112915_bib283","doi-asserted-by":"crossref","first-page":"e13169","DOI":"10.1111\/acel.13169","article-title":"Exploration of multi-target effects of 3-benzoyl-5-hydroxychromen-2-one in Alzheimer\u2019s disease cell and mouse models","volume":"19","author":"Lin","year":"2020","journal-title":"Aging Cell"},{"key":"10.1016\/j.ejmech.2020.112915_bib285","doi-asserted-by":"crossref","first-page":"4693","DOI":"10.1016\/j.bmc.2018.08.007","article-title":"Synthesis and evaluation of 1,2,3,4-tetrahydro-1-acridone analogues as potential dual inhibitors for amyloid-beta and tau aggregation","volume":"26","author":"Lv","year":"2018","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2020.112915_bib286","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.ejmech.2016.06.008","article-title":"Neuroprotective effect of synthetic chalcone derivatives as competitive dual inhibitors against \u03bc-calpain and cathepsin B through the downregulation of tau phosphorylation and insoluble A\u03b2 peptide formation","volume":"121","author":"Jeon","year":"2016","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2020.112915_bib287","doi-asserted-by":"crossref","first-page":"3464","DOI":"10.1111\/jcmm.13624","article-title":"Development of GMP-1 a molecular chaperone network modulator protecting mitochondrial function and its assessment in fly and mice models of Alzheimer\u2019s disease","volume":"22","author":"Pavlov","year":"2018","journal-title":"J.\u00a0Cell Mol. Med."},{"key":"10.1016\/j.ejmech.2020.112915_bib288","doi-asserted-by":"crossref","first-page":"695","DOI":"10.3233\/JAD-190695","article-title":"Metal binding by GMP-1 and its pyrimido [1, 2]benzimidazole analogs confirms protection against amyloid-\u03b2 associated neurotoxicity","volume":"73","author":"Kumar","year":"2020","journal-title":"J.\u00a0Alzheimers Dis."},{"key":"10.1016\/j.ejmech.2020.112915_bib289","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.jconrel.2019.10.034","article-title":"Nanoparticle-mediated approaches for Alzheimer\u2019s disease pathogenesis, diagnosis, and therapeutics","volume":"314","author":"Hettiarachchi","year":"2019","journal-title":"J.\u00a0Contr. Release"},{"key":"10.1016\/j.ejmech.2020.112915_bib290","doi-asserted-by":"crossref","first-page":"12833","DOI":"10.1021\/acsomega.9b01411","article-title":"Protein-capped metal nanoparticles inhibit tau aggregation in Alzheimer\u2019s disease","volume":"4","author":"Sonawane","year":"2019","journal-title":"ACS Omega"},{"issue":"12","key":"10.1016\/j.ejmech.2020.112915_bib291","doi-asserted-by":"crossref","first-page":"2911","DOI":"10.1007\/s00259-020-04788-w","article-title":"Early-phase [18F]PI-2620 tau-PET imaging as a surrogate marker of neuronal injury","volume":"47","author":"Beyer","year":"2020","journal-title":"Eur. J. Nucl. Med. Mol. Imag."},{"key":"10.1016\/j.ejmech.2020.112915_bib292","article-title":"Current and future treatments in Alzheimer disease: an update","volume":"12","author":"Yiannopoulou","year":"2020","journal-title":"J.\u00a0Cent. Nerv. Syst. Dis."},{"key":"10.1016\/j.ejmech.2020.112915_bib293","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1055\/s-0039-1678581","article-title":"Current and future treatments in Alzheimer\u2019s disease","volume":"39","author":"Atri","year":"2019","journal-title":"Semin. Neurol."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523420308874?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523420308874?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T22:35:47Z","timestamp":1776119747000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523420308874"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":283,"alternative-id":["S0223523420308874"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2020.112915","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Small molecule therapeutics for tauopathy in Alzheimer\u2019s disease: Walking on the path of most resistance","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2020.112915","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Author(s). Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"112915"}}